Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets
Posted On: 2020-12-30 22:32:43 (Time Zone: Arizona, USA)
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has received final approval by the United States Food & Drug Administration (U.S. FDA) for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg, the generic version of Cialis®1 Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, of Eli Lilly and Company.
According to IQVIATM sales data for the 12 month period ending November 2020, the Cialis® Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg market2 achieved annual sales of approximately $125.5 million .
Glenmark has also received tentative approval by the U.S. FDA for Gabapentin Enacarbil ExtendedRelease Tablets, 300 mg and 600 mg, the generic version of Horizant®1 Extended-Release Tablets, 300 mg and 600 mg, of Arbor Pharmaceuticals, LLC. The Horizant® market achieved annual sales of approximately $99.5 million.